Literature DB >> 26164583

How omalizumab came to be studied as a therapy for chronic spontaneous/idiopathic urticaria.

Allen P Kaplan1, Kusumam Joseph2, Sarbjit S Saini3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26164583     DOI： 10.1016/j.jaip.2015.04.008

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  2 in total

1.  Combination therapy with omalizumab and an immune-suppressive agent for resistant chronic spontaneous rrticaria - A real-life experience.

Authors:  Ramit Maoz-Segal; Tanya Levy; Soad Haj-Yahia; Irena Offengenden; Mona Iancovich-Kidon; Nancy Agmon-Levin
Journal:  World Allergy Organ J       Date:  2020-08-04       Impact factor: 4.084

Review 2.  Chronic Spontaneous Urticaria: The Devil's Itch.

Authors:  Sarbjit S Saini; Allen P Kaplan
Journal:  J Allergy Clin Immunol Pract       Date:  2018 Jul - Aug
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.